Skip to main content
OpenTrials
Completed

NCT Number: NCT06441409

Effect of Lifestyle Intervention on Mobilization of Fat Storage and Iron Deposition in Obesity

The goal of this clinical trial is to learn if calorie-restricted balanced diet could uniquely influence various fat storage pools and iron deposition and explore the relationships between fat or iron deposition loss in specific locations and glucose metabolism. The main questions it aims to answer are:

After lifestyle intervention, which part of the body shows the fastest fat mobilization? Which part shows the slowest fat mobilization? Which area's fat mobilization is most related to the alleviation of glucose metabolism? Is there a relationship between the fat deposition in organs and the iron deposition in organs?

Researchers will compare the liver fat, pancreatic fat, visceral fat, subscutaneous fat, liver and pancrease iron depositon after lifestyle intervention using self pre-and post-control .

Participants will:

Receive the lifestyle intervention in outpatient. Visit the clinic once after 6 months for checkups and tests. Keep a diary of their diet.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

the Third Xiangya Hospital of Central South University

Changsha, Hunan, 410013, China

About this study

Fat mobilization status is assessed using magnetic resonance, while the relief of glucose metabolism is determined based on the results of the OGTT before and after life style intervention.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age between 18 and 70 years
  • have a BMI greater than 28.0 kg/m2
  • exhibit abdominal obesity, defined as a waist circumference of at least 90 cm for men and 85 cm for women
  • willing to undergo a 6-month lifestyle intervention

Exclusion criteria

  • For newly diagnosed patients with type 2 diabetes: those with fasting blood glucose ≥ 11.1 mmol/L, random blood glucose ≥ 16.7 mmol/L, or HbA1c ≥ 9.0%, or those exhibiting significant hyperglycemic symptoms, who need to start antidiabetic medication treatment immediately;
  • a prior history of pancreatic diseases;
  • combination of drug-induced hepatitis, autoimmune hepatitis, and viral hepatitis;
  • with a definitive diagnosis of diabetes who have already started medication treatment;
  • severe complications from type 2 diabetes or other significant diseases;
  • usage of drugs affecting body weight, insulin sensitivity, or metabolic-associated fatty liver disease in the past three months (such as insulin, glucocorticoids, thiazolidinediones, metformin, SGLT-2 inhibitors, or GLP-1 receptor agonists);
  • with malignant tumors;
  • acute or chronic infection;
  • with elevated transaminase levels of unknown cause;
  • hemochromatosis;
  • with iron deficiency anemia who are receiving iron supplementation;
  • who have donated blood or received a transfusion within the past six months;
  • who have experienced cardiovascular events within the past six months;
  • with acute or chronic blood loss;
  • alcohol dependence, defined as ethanol intake exceeding 140 g/week for men and 70 g/week for women;
  • pregnant and lactating women.

Treatment and study plan

Lifestyle Intervention

Behavioral

Patients were intervened with lifestyle only and returned to clinic for tests in 6 months.

Lifestyle intervention included the diet and exercise. Diet was an energy-restricted balanced diet. Exercise requires 5 days a week and 30 minutes every day.

Primary outcomes

  1. The site-specific fat mobilization after 6 months' lifestyle intervention.

    Time frame: After 6 months intervention, patients were return to hospital for MRI analysis.

    Defined by percentage MRI-based fat loss. Calculated as (initial measurement minus follow-up measurement) / (initial measurement) × 100 and predefined to be assessed at 6-month follow-up. MRI scans were acquired with an INGENIA ELITION X (Philips Medical Systems Nederland B.V.).

  2. The site-specific iron deposition mobilization after 6 months' lifestyle intervention.

    Time frame: Patients were return to hospital for MRI and serum tests after lifestyle intervention for 6 months.

    Defined by percentage MRI-based organ iron content loss. Calculated as (initial measurement minus follow-up measurement) / (initial measurement) × 100 and predefined to be assessed at 6-month follow-up. MRI scans were acquired with an INGENIA ELITION X (Philips Medical Systems Nederland B.V.).

Secondary outcomes

  1. The correlation between liver fat and liver iron.

    Time frame: Patients were return to hospital for MRI and serum tests after lifestyle intervention for 6 months.

    Categorical variables were summarized as numbers (percentages), continuous variables with normal distributions as means (SDs), and continuous variables with non-normal distributions as medians (interquartile ranges [IQRs]). Treatment-induced changes were tested by the paired t test and Wilcoxon signed-rank test, as appropriate. The unpaired t test, Mann-Whitney U test, and Kruskal-Wallis test were used for group comparisons. Correlations between site-specific fat mobilization and clinical outcomes were investigated by calculating Pearson correlation coefficients and Pearson partial correlation coefficients. Two-sided P < 0.05 was considered statistically significant. Statistical analyses were performed using R software version 4.1.2 (http://www.r-project.org/).

Sponsors and collaborators

Lead sponsor

The Third Xiangya Hospital of Central South University

Other

Registry information

Official study title

Effect of Calorie-restricted Balanced Diet on Mobilization of Fat Storage Pools and Iron Deposition in Individuals With Obesity

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jun 4, 2024
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.